Poll

POLL: Will you use biosimilars in your ophthalmic practice?

Author(s):

Sheryl Stevenson

Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.

Will you use biosimilars in your ophthalmic practice?

Yes, I plan to use biosimilars in my practice
No, I do not plan to use biosimilars in my practice

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
Related Content
Q&A: Yasha S. Modi, MD, on retinal nonperfusion in diabetic retinopathy
May 20th 2025

Q&A: Yasha S. Modi, MD, on retinal nonperfusion in diabetic retinopathy

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

NIH researchers develop custom AI to enhance images of RPE cells
May 18th 2025

NIH researchers develop custom AI to enhance images of RPE cells

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Image credit: AdobeStock/peshkova)
May 17th 2025

Q&A: Joaquin De Rojas, MD, on ASCRS 2025 Best Paper of Session for advancing AK with machine learning

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
May 16th 2025

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies

© 2025 MJH Life Sciences

All rights reserved.